Navigation Links
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Date:8/1/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Aug. 1 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, and is being conducted at 68 trial sites in the U.S.

"We have had great success in recruiting patients into the trial, which is a testament to the promise of our approach and the efforts of our investigators," said Mr. Kevin Giese, President and CEO. "Since initiating this trial in June 2007 we have been delighted by the enthusiasm of the patients and clinical groups participating across the U.S."

MBP8298 (dirucotide) is currently being developed in three late-stage clinical trials:

1. MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS

(SPMS) patients in Canada and Europe.

2. MAESTRO-03: A pivotal phase III trial for SPMS patients in the United

States.

3. MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)

patients in Europe.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either MBP8298 (dirucotide) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About MBP8298 (dirucotide)

-----------------
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... studies for its newly developed Bruton,s tyrosine kinase ... been completed. The results of these preclinical evaluations ... Drug Administration. The feedback received from the Agency ... first-in-human study. Additional preclinical work is required to ...
(Date:2/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has ... Trypsin" report to their offering. , ... comprehensive data on Trypsin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:2/27/2015)... 27, 2015 The fully automated ... UC) can sequentially analyze up to 48 samples ... high-sensitivity detection of targets by mass spectrometry. ... fulfill the measurement requirements of a wide range ... drug delivery and search for disease biomarkers, additives ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... Scientific Corporation (NYSE: BSX ) has ... with left main coronary disease who were treated ... SYNTAX-LE MANS is a substudy of the landmark ...
... ( http://www.gene2drug.com ) -- the ... science industry -- announces the publication of its latest ... for Commercial Suppliers, Vol. III." Given the highly ... report is designed to create opportunities for differentiation by ...
... Cholesterol Test for determining heart disease riskBIRMINGHAM, Ala., May ... developer of the VAP Cholesterol Test, has announced it ... and report apolipoprotein B100 (apoB) using the Vertical Auto ... of the VAP Cholesterol Test to accurately report apoB, ...
Cached Biology Technology:SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5BioInformatics, LLC New Report -- The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III 2Atherotech Receives Patent for ApoB Measurement 2Atherotech Receives Patent for ApoB Measurement 3
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... PITTSBURGH, Oct. 23 A new study suggests that viruses ... cells while promoting the growth of surviving cells with cancerous ... wiping out normal cells that support the replication of viruses ... their circuitry. When this process is repeated over and over, ...
... David Jones, a fisheries oceanographer at the Cooperative Institute for ... Miamis Rosenstiel School, set out to design a better light ... invention would contribute to the discovery of a new species. ... known description, his catch turned out to be the answer ...
... Captains Log originally used with individuals diagnosed ... learning disabilities is being adapted to rehabilitate ... Michael Boivin, a Michigan State University associate ... and Bruno Giordani, a University of Michigan associate ...
Cached Biology News:Study proposes new theory of how viruses may contribute to cancer 2New light trap captures larval stage of new species; DNA barcode technology used 2MSU researcher helps develop computer game for Ugandan children recovering from cerebral malaria 2
...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... is a protein ribonuclease inhibitor that noncovalently binds ... inhibition is seen with RNase 1, T1, T2, ... from human placental ribonuclease inhibitor in that it ... does not release active RNase in the absence ...
... Inkjet Printer) is a revolutionary new ... Protein Macroarray Analysis, developed in conjunction ... strategy compliments established protocols in resolving ... proteins isoelectric point and apparent molecular ...
Biology Products: